Patents by Inventor Alex Levitzki
Alex Levitzki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220339189Abstract: A method of treating cancer may include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate may consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety may be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: March 2, 2022Publication date: October 27, 2022Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 11298376Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: GrantFiled: March 7, 2019Date of Patent: April 12, 2022Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 10543232Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).Type: GrantFiled: March 8, 2019Date of Patent: January 28, 2020Assignee: TargImmune Therapeutics AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20190262395Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: March 7, 2019Publication date: August 29, 2019Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20190192563Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).Type: ApplicationFiled: March 8, 2019Publication date: June 27, 2019Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 10278991Abstract: A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: GrantFiled: May 14, 2015Date of Patent: May 7, 2019Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20170072063Abstract: A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: May 14, 2015Publication date: March 16, 2017Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 7964399Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Type: GrantFiled: March 15, 2004Date of Patent: June 21, 2011Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Yissum Research, Development Company of the Hebrew University of JerusalemInventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Publication number: 20050107321Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Type: ApplicationFiled: March 15, 2004Publication date: May 19, 2005Inventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Patent number: 6872699Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and truncated Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Type: GrantFiled: January 23, 2001Date of Patent: March 29, 2005Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften, E.V.Inventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Publication number: 20020081650Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described.Type: ApplicationFiled: January 23, 2001Publication date: June 27, 2002Inventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Patent number: 6331555Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: July 27, 1999Date of Patent: December 18, 2001Assignees: University of California, Yissum Research Development Company of the Hebrew University of Jerusalem, Biosignal LTD, Sugen, Inc., Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Klaus P. Hirth, Elaina Mann, Laura K. Shawyer, Axel Ullrich, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Peng Cho Tang, Reiner Lammers
-
Patent number: 5990141Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: January 6, 1995Date of Patent: November 23, 1999Assignee: Sugen Inc.Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang
-
Patent number: 5851999Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Type: GrantFiled: May 22, 1995Date of Patent: December 22, 1998Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften ev., Yissum Research, Development Company of the Hebrew University of JerusalemInventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
-
Patent number: 5700823Abstract: Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.Type: GrantFiled: January 7, 1994Date of Patent: December 23, 1997Assignees: Sugen, Inc., Biosignal L.T.D., Yissum Research Development Company, Hebrew University of Jerusalem, Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgy Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers
-
Patent number: 5700822Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.Type: GrantFiled: June 1, 1995Date of Patent: December 23, 1997Assignee: The Regents of the University of CaliforniaInventors: Klaus Peter Hirth, Donna Pruess Schwartz, Elaina Mann, Laura Kay Shawver, Gyorgi Keri, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Axel Ullrich, Reiner Lammers, Fairooz F. Kabbinavar, Dennis Slamon, Peng Cho Tang